The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Receptor Activity-Modifying Proteins Differentially Modulate the G Protein-Coupling Efficiency of Amylin Receptors
Open accessAbstract
Receptor activity-modifying proteins (RAMPs) 1, 2, and 3 are prototypic G protein-coupled receptor accessory proteins that can alter not only receptor trafficking but also receptor phenotype. Specific RAMP interaction with the calcitonin receptor (CTR) generates novel and distinct receptors for the peptide amylin; however, the role of RAMPs in receptor signaling is not understood. The current study demonstrates that RAMP interaction with the CTRa in COS-7 or HEK-293 cells leads to selective modulation of signaling pathways activated by the receptor complex. There was a 20- to 30-fold induction in amylin potency at CTR/RAMP1 (AMY1) and CTR/RAMP3 (AMY3) receptors, compared with CTR alone, for formation of the second-messenger cAMP that parallels an increase in amylin binding affinity. In contrast, only 2- to 5-fold induction of amylin potency was seen for mobilization of intracellular Ca++ or activation of ERK1/2. In addition, in COS-7 cells, the increase in amylin potency for Ca++ mobilization was 2-fold greater for AMY3 receptors, compared with AMY1 receptors and this paralleled the relative capacity of overexpression of Gαq proteins to augment induction of high affinity 125I-amylin binding. These data demonstrate that RAMP-complexed receptors have a different signaling profile to CTRs expressed in the absence of RAMPs, and this is likely due to direct effects of the RAMP on G protein-coupling efficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“4) Signaling: studies of the amylin receptors (AMY 1-3 ) found that downstream signaling pathways of intracellular calcium production depend on the specific interacting RAMP and suggested that RAMP-complexed receptors have a different signaling profile to that of CTR expressed in the absence of RAMPs (152).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [152]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134
Poyner, D. R., Sexton, P. M., Marshall, I., Smith, D. M., Quirion, R., Born, W., Muff, R., Fischer, J. A., & Foord, S. M. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.233 · Cited by 804
Self-citationChristopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Gao, Y., Fraser, N. J., Main, M. J., Foord, S. M., & Sexton, P. M. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.1.235 · Cited by 486
Self-citationNovel Receptor Partners and Function of Receptor Activity-modifying Proteins
Christopoulos, A., Christopoulos, G., Morfis, M. M., Udawela, M., Laburthe, M., Couvineau, A., Kuwasako, K., Tilakaratne, N., & Sexton, P. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200629200 · Cited by 309
Self-citationGPCR interacting proteins (GIP)
Bockaert, J., Fagni, L., Dumuis, A., & Marin, P. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.06.004 · Cited by 262
Hay, D. L., Poyner, D. R., & Sexton, P. M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.015 · Cited by 239
Self-citationPharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes
Hay, D. L., Christopoulos, G., Christopoulos, A., Poyner, D. R., & Sexton, P. M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008615 · Cited by 213
Self-citationACCESSORY PROTEINS FOR G PROTEINS: Partners in Signaling
Sato, M., Blumer, J., Simon, V., & Lanier, S. M. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141115 · Cited by 173
Tilakaratne, N., Christopoulos, G., van der Westhuizen, E. T., Foord, S. M., & Sexton, P. M. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39040-8 · Cited by 165
Self-citationSexton, P. M., Findlay, D. M., & Martin, T. J. (1999) · Current Medicinal Chemistry · doi:10.2174/092986730611220401164504 · Cited by 163
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Islet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus
Westermark, P., Andersson, A., & Westermark, G. T. (2011) · Physiological Reviews · doi:10.1152/physrev.00042.2009 · Cited by 1,044
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 561
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Russo, A. F., & Hay, D. L. (2022) · Physiological Reviews · doi:10.1152/physrev.00059.2021 · Cited by 415
Koole, C., Wootten, D. L., Simms, J., Valant, C., Sridhar, R., Woodman, O. L., Miller, L. J., Summers, R. J., Christopoulos, A., & Sexton, P. M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065664 · Cited by 225
Self-citationBiased Allosteric Modulators: New Frontiers in GPCR Drug Discovery
Slosky, L. M., Caron, M. G., & Barak, L. S. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.12.005 · Cited by 214
Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles
Hay, D. L., & Pioszak, A. A. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103120 · Cited by 197
Regulation of signal transduction by calcitonin gene-related peptide receptors
Walker, C. S., Conner, A. C., Poyner, D. R., & Hay, D. L. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.06.006 · Cited by 157
Chaperoning G Protein-Coupled Receptors: From Cell Biology to Therapeutics
Tao, Y., & Conn, P. M. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1121 · Cited by 149
The Activity of Peptides of the Calcitonin Family in Bone
Naot, D., Musson, D. S., & Cornish, J. (2019) · Physiological Reviews · doi:10.1152/physrev.00066.2017 · Cited by 141
Endogenous Allosteric Modulators of G Protein–Coupled Receptors
van der Westhuizen, E. T., Valant, C., Sexton, P. M., & Christopoulos, A. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.221606 · Cited by 145
Self-citationControl of energy homeostasis by amylin
Lutz, T. A. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0905-1 · Cited by 139
Allostery and biased agonism at class B G protein-coupled receptors
Wootten, D., Miller, L. J., Koole, C., Christopoulos, A., & Sexton, P. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00049 · Cited by 112
Self-citationBower, R. L., & Hay, D. L. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13496 · Cited by 104
Bailey, R., Walker, C. S., Ferner, A. H., Loomes, K., Prijic, G., Halim, A., Whiting, L., Phillips, A., & Hay, D. L. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01717.x · Cited by 102
Modulation of immune responses by the neuropeptide CGRP
Holzmann, B. (2011) · Amino Acids · doi:10.1007/s00726-011-1161-2 · Cited by 104
Fu, W., Ruangkittisakul, A., MacTavish, D., Shi, J., Ballanyi, K., & Jhamandas, J. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.331181 · Cited by 95
A structural basis for amylin receptor phenotype
Cao, J., Belousoff, M. J., Liang, Y.-L., Johnson, R. M., Josephs, T. M., Fletcher, M. M., Christopoulos, A., Hay, D. L., Danev, R., Wootten, D. L., et al. (2022) · Science · doi:10.1126/science.abm9609 · Cited by 92
Self-citationBrainstem mechanisms of amylin-induced anorexia
Potes, C. S., & Lutz, T. A. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.03.001 · Cited by 93
Alexander, S., Mathie, A. A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_3.x · Cited by 90
Liang, Y.-L., Belousoff, M. J., Fletcher, M. M., Zhang, X., Khoshouei, M., Deganutti, G., Koole, C., Furness, S. G. B., Miller, L. J., Hay, D. L., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00080 · Cited by 89
Self-citationWootten, D. L., Lindmark, H., Kadmiel, M., Willcockson, H. H., Caron, K. M., Barwell, J., Drmota, T., & Poyner, D. R. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02202.x · Cited by 85
Actions of β-Amyloid Protein on Human Neurons Are Expressed through the Amylin Receptor
Jhamandas, J. H., Li, Z., Westaway, D. A., Yang, J., Jassar, S., & MacTavish, D. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.022 · Cited by 85
Calcitonin and calcitonin receptor‐like receptors: common themes with family B GPCRs?
Barwell, J., Gingell, J. J., Watkins, H. A., Archbold, J. K., Poyner, D. R., & Hay, D. L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01525.x · Cited by 80
Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin
Bower, R. L., Yule, L. R., Rees, T. A., Deganutti, G., Hendrikse, E. R., Harris, P. W. R., Kowalczyk, R., Ridgway, Z. M., Wong, A. G., Swierkula, K., et al. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00002 · Cited by 80
Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2)
Weston, C. A., Lu, J. N., Li, N., Barkan, K., Richards, G. O., Roberts, D. J., Skerry, T. M., Poyner, D. R., Pardamwar, M., Reynolds, C. A., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624601 · Cited by 76
Calcitonin and Amylin Receptor Peptide Interaction Mechanisms
Lee, S. M., Hay, D. L., & Pioszak, A. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.713628 · Cited by 76
Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations
Xie, J., Guo, J., Kanwal, Z., Wu, M., Lv, X., Ibrahim, N. A., Li, P., Buabeid, M. A., Arafa, E. A., & Sun, Q. (2020) · International Journal of Endocrinology · doi:10.1155/2020/3236828 · Cited by 77
Modulating receptor function through RAMPs: can they represent drug targets in themselves?
Sexton, P. M., Poyner, D. R., Simms, J., Christopoulos, A., & Hay, D. L. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.009 · Cited by 72
Self-citationFletcher, M. M., Keov, P., Truong, T. T., Mennen, G., Hick, C. A., Zhao, P., Furness, S. G. B., Kruse, T., Clausen, T. R., Wootten, D. L., et al. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000567 · Cited by 69
Self-citationAmylin activates distributed CNS nuclei to control energy balance
Mietlicki‐Baase, E. G., & Hayes, M. R. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.01.013 · Cited by 65
Liberini, C. G., Boyle, C. N., Cifani, C., Vènniro, M., Hope, B. T., & Lutz, T. A. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13163 · Cited by 66
An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology
Gingell, J. J., Simms, J., Barwell, J., Poyner, D. R., Watkins, H. A., Pioszak, A. A., Sexton, P. M., & Hay, D. L. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.12 · Cited by 60
Self-citationLutz, T. A. (2022) · Appetite · doi:10.1016/j.appet.2022.105965 · Cited by 59
Activity of Pramlintide, Rat and Human Amylin but not Aβ1–42 at Human Amylin Receptors
Gingell, J. J., Hendrikse, E. R., & Hay, D. L. (2013) · Endocrinology · doi:10.1210/en.2013-1658 · Cited by 58
Yan, L.-M., Velkova, A., Tatarek-Nossol, M., Rammes, G., Sibaev, A., Andreetto, E., Kracklauer, M., Bakou, M., Malideli, E., Göke, B., et al. (2013) · Angewandte Chemie · doi:10.1002/anie.201302840 · Cited by 55
Reiner, D. J., Mietlicki‐Baase, E. G., Olivos, D. R., McGrath, L. E., Zimmer, D. J., Koch‐Laskowski, K., Krawczyk, J., Turner, C. A., Noble, E. E., Hahn, J. D., et al. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.12.028 · Cited by 52
Potes, C. S., Boyle, C. N., Wookey, P. J., Riediger, T., & Lutz, T. A. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00380.2011 · Cited by 51
Amylin and Leptin: Co-Regulators of Energy Homeostasis and Neuronal Development
Levin, B. E., & Lutz, T. A. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.11.004 · Cited by 50
Pioszak, A. A., & Hay, D. L. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.01.001 · Cited by 50
The Molecular Control of Calcitonin Receptor Signaling
Maso, E. D., Glukhova, A., Zhu, Y., García‐Nafría, J., Tate, C. G., Atanasio, S., Reynolds, C. A., Ramírez-Aportela, E., Carazo, J. M., Hick, C. A., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00056 · Cited by 48
Self-citationHarikumar, K. G., Simms, J., Christopoulos, G., Sexton, P. M., & Miller, L. J. (2009) · Biochemistry · doi:10.1021/bi901326k · Cited by 48
Self-citationQi, T., Dong, M., Watkins, H. A., Wootten, D. L., Miller, L., & Hay, D. L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02197.x · Cited by 47
Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins
Kotliar, I. B., Lorenzen, E., Schwenk, J. M., Hay, D. L., & Sakmar, T. P. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000180 · Cited by 50
Metabolic hormone action in the VTA: Reward-directed behavior and mechanistic insights
Geisler, C. E., & Hayes, M. R. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114236 · Cited by 51
Jhamandas, J. H., & MacTavish, D. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0656-3 · Cited by 45
Receptor activity-modifying proteins; multifunctional G protein-coupled receptor accessory proteins
Hay, D. L., Walker, C. S., Gingell, J. J., Ladds, G., Reynolds, C. A., & Poyner, D. R. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150237 · Cited by 45
Walker, C. S., Sundrum, T., & Hay, D. L. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12541 · Cited by 43
Dunn-Meynell, A. A., Foll, C. L., Johnson, M. D., Lutz, T. A., Hayes, M. R., & Levin, B. E. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00462.2015 · Cited by 43
The expanding repertoire of receptor activity modifying protein (RAMP) function
Klein, K. R., Matson, B. C., & Caron, K. M. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1128875 · Cited by 40
Molecular Mechanisms of Class B GPCR Activation: Insights from Adrenomedullin Receptors
Garelja, M. L., Au, M., Brimble, M. A., Gingell, J. J., Hendrikse, E. R., Lovell, A., Prodan, N., Sexton, P. M., Siow, A., Walker, C. S., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00083 · Cited by 40
Self-citationGarelja, M. L., Bower, R. L., Brimble, M. A., Chand, S., Harris, P. W. R., Jamaluddin, A., Petersen, J. S. S. M., Siow, A., Walker, C. S., & Hay, D. L. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15628 · Cited by 37
Zakariassen, H. L., John, L. M., & Lutz, T. A. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13427 · Cited by 37
Amylin Receptor Signaling in the Nucleus Accumbens Negatively Modulates μ-opioid-Driven Feeding
Baisley, S. K., & Baldo, B. A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.153 · Cited by 36
Sekiguchi, T., Kuwasako, K., Ogasawara, M., Takahashi, H., Matsubara, S., Osugi, T., Muramatsu, I., Sasayama, Y., Suzuki, N., & Satake, H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664003 · Cited by 38
RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling
Cegla, J., Jones, B. J., Gardiner, J., Hodson, D. J., Marjot, T., McGlone, E. R., Tan, T., & Bloom, S. R. (2017) · Endocrinology · doi:10.1210/en.2016-1755 · Cited by 34
Translational neuropharmacology: the use of human isolated gastrointestinal tissues
Sanger, G. J., Broad, J., Kung, V., & Knowles, C. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02198.x · Cited by 36
Structure–function relationships of the N‐terminus of receptor activity‐modifying proteins
Qi, T., & Hay, D. L. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00541.x · Cited by 36
Woolley, M. J., Reynolds, C. A., Simms, J., Walker, C. S., Mobarec, J. C., Garelja, M. L., Conner, A. C., Poyner, D. R., & Hay, D. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.07.005 · Cited by 35
Trikha, S., & Jeremic, A. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073080 · Cited by 34
Pal, J., Patil, V. S., Kumar, A., Kaur, K., Sarkar, C., & Somasundaram, K. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1901 · Cited by 34
Molecular chaperones and G protein-coupled receptor maturation and pharmacology
Tao, Y. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110862 · Cited by 32
Maso, E. D., Zhu, Y., Pham, V., Reynolds, C. A., Deganutti, G., Hick, C. A., Yang, D., Christopoulos, A., Hay, D. L., Wang, M.-W., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.02.005 · Cited by 29
Self-citationAmylin in Alzheimer's disease: Pathological peptide or potential treatment?
Mietlicki‐Baase, E. G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.016 · Cited by 30
Arrigoni, S., Foll, C. L., Cabak, A., Lundh, S. H., Raun, K., John, L. M., & Lutz, T. A. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15376 · Cited by 29
Geisler, C. E., Décarie-Spain, L., Loh, M. K., Trumbauer, W., Gaisinsky, J., Klug, M. E., Pelletier, C., Davis, J. F., Schmidt, H. D., Roitman, M. F., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.07.011 · Cited by 25
Understanding RAMPs Through Genetically Engineered Mouse Models
Kadmiel, M., Fritz-Six, K. L., & Caron, K. M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-2364-5_5 · Cited by 26
The calcitonin-like system is an ancient regulatory system of biomineralization
Cardoso, J. C. R., Félix, R. C., Ferreira, V., Peng, M., Zhang, X., & Power, D. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-64118-w · Cited by 23
Liu, C., Wu, G., Fu, X., Mo, X., Zhao, L., Hu, H., Zhu, S., & Hou, Y. (2015) · Biology of Reproduction · doi:10.1095/biolreprod.115.128579 · Cited by 21
Zhou, Q., Li, G., Deng, X., He, X., Chen, L., Wu, C. J., Shi, Y., Wu, K., Mei, L., Lu, J., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01875.x · Cited by 21
Aftabizadeh, M., Tatarek‐Nossol, M., Andreetto, E., Bounkari, O. E., Kipp, M., Beyer, C., Latz, E., Bernhagen, J., & Kapurniotu, A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00260 · Cited by 20
Skovbjerg, G., Roostalu, U., Hansen, H. H., Lutz, T. A., Foll, C. L., Salinas, C. G., Skytte, J. L., Jelsing, J., Vrang, N., & Hecksher‐Sørensen, J. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15254 · Cited by 19
Islet amyloid toxicity: From genesis to counteracting mechanisms
Marmentini, C., Branco, R. C. S., Boschero, A. C., & Kurauti, M. A. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30600 · Cited by 19
Ostrovskaya, A., Hick, C. A., Hutchinson, D. S., Stringer, B. W., Wookey, P. J., Wootten, D. L., Sexton, P. M., & Furness, S. G. B. (2019) · BMC Cancer · doi:10.1186/s12885-019-5369-y · Cited by 19
Self-citationSingh, S., Trikha, S., Bhowmick, D. C., Sarkar, A. A., & Jeremic, A. M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-17344-3_4 · Cited by 18
RAMPs regulate signalling bias and internalisation of the GIPRPreprint
Harris, M., Mackie, D. I., Pawlak, J. B., Carvalho, S., Truong, T. T., Safitri, D., Yeung, H. Y., Routledge, S. J., Harper, M. T., Al‐Zaid, B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.08.436756 · Cited by 19
Self-citationFoll, C. L., & Lutz, T. A. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190034 · Cited by 27
The effects of RAMPs upon cell signalling
Routledge, S. J., Ladds, G., & Poyner, D. R. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.03.033 · Cited by 16
Receptor Activity Modifying Proteins and Their Potential as Drug Targets
Wootten, D. L., Simms, J., Hay, D. L., Christopoulos, A., & Sexton, P. M. (2010) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(10)91003-x · Cited by 16
Self-citationSexton, P. M., Poyner, D. R., Simms, J., Christopoulos, A., & Hay, D. L. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-2364-5_6 · Cited by 12
Self-citationKrizhanovskii, C., Fred, R. G., Oskarsson, M. E., Westermark, G. T., & Welsh, N. (2017) · Upsala Journal of Medical Sciences · doi:10.1080/03009734.2017.1368745 · Cited by 11
Lee, S. M. (2021) · Biomolecules · doi:10.3390/biom11091364 · Cited by 12
Chidiac, P. (2015) · Methods · doi:10.1016/j.ymeth.2015.08.011 · Cited by 12
Pham, V., Zhu, Y., Maso, E. D., Reynolds, C. A., Deganutti, G., Atanasio, S., Hick, C. A., Yang, D., Christopoulos, A., Hay, D. L., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00010 · Cited by 12
Self-citationFunctional characterization of two human receptor activity-modifying protein 3 variants
Bailey, R. J., Bradley, J., Poyner, D. R., Rathbone, D. L., & Hay, D. L. (2009) · Peptides · doi:10.1016/j.peptides.2009.12.016 · Cited by 12
The role of amylin, a gut–brain axis hormone, in metabolic and neurological disorders
Muhammad, T., Pastore, S. F., Good, K., Yu, W. H., & Vincent, J. B. (2025) · FASEB BioAdvances · doi:10.1096/fba.2024-00151 · Cited by 12
Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors
Piper, N. B. C., Whitfield, E. A., Stewart, G. D., Xu, X., & Furness, S. G. B. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115115 · Cited by 11
Self-citationGiansanti, M., Gabrieli, A. D., Prete, S. P., Ottone, T., Divona, M. D., Karimi, T., Ciccarone, F., Voso, M. T., Graziani, G., & Faraoni, I. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000537 · Cited by 11
The Structure of the CGRP and Related Receptors
Simms, J., Routledge, S. J., Uddin, R., & Poyner, D. R. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_132 · Cited by 10
Abdelmagid, N., Bereczky-Veress, B., Guerreiro‐Cacais, A. O., Bergman, P., Luhr, K. M., Bergström, T. B., Sköldenberg, B., Piehl, F., Olsson, T. P., & Diez, M. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002753 · Cited by 10
Kuwasako, K., Kitamura, K., Nagata, S., & Kato, J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.04.097 · Cited by 10
The processing intermediate of human amylin, pro-amylin(1–48), has in vivo and in vitro bioactivity
Mazzini, G., Foll, C. L., Boyle, C. N., Garelja, M. L., Zhyvoloup, A., Miller, M. E. T., Hay, D. L., Raleigh, D. P., & Lutz, T. A. (2024) · Biophysical Chemistry · doi:10.1016/j.bpc.2024.107201 · Cited by 9
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
Zong, L., Zhang, Z., Li, X., Jie, J., Jiang, X., Wang, Z., Liu, W., Shen, X., Feng, X., Huang, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01120 · Cited by 8
Islet amyloid polypeptide does not suppress pancreatic cancer
Taylor, A. J., Panzhinskiy, E., Orban, P. C., Lynn, F. C., Schaeffer, D. F., Johnson, J. D., Kopp, J. L., & Verchere, C. B. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101667 · Cited by 7
Yan, L.-M., Velkova, A., Tatarek‐Nossol, M., Rammes, G., Sibaev, A., Andreetto, E., Kracklauer, M., Bakou, M., Malideli, E., Göke, B., et al. (2013) · Angewandte Chemie · doi:10.1002/ange.201302840 · Cited by 6
Understanding Amylin Receptors
Just, R., Simms, J., Furness, S. G. B., Christopoulos, A., & Sexton, P. M. (2009) · Springer eBooks · doi:10.1007/978-90-481-2909-6_3 · Cited by 7
Self-citationCalcitonin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
Hay, D. L., Poyner, D. R., & Walker, C. S. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f11/2019.4 · Cited by 6
The Molecular Physiopathogenesis of Islet Amyloidosis
Bhowmick, D. C., Singh, S., Trikha, S., & Jeremic, A. M. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_62 · Cited by 8
Servizi, S., Corrigan, R. R., & Casadesús, G. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200318151146 · Cited by 6
Amylin Pharmacology in Alzheimer’s Disease Pathogenesis and Treatment
Casadesús, G., Corrigan, R. R., & Piontkivska, H. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211201093147 · Cited by 7
Metadata
- Authors
- Morfis, M., Tilakaratne, N., Furness, S. G. B., Christopoulos, G., Werry, T. D., Christopoulos, A., & Sexton, P. M.
- Affiliations
- The University of Melbourne (AU)
- Monash University (AU)
- Corresponding author
- Sexton, Patrick M.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2008-07-03
- Volume
- 149
- Issue
- 11
- Pages
- 5423-5431
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2101979449
- Semantic Scholar
- 2ad08a2ccb8e57ba63eab72d9571651ccbdaf556
- Cited by
- 134
- References
- 23
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 2 · 2023: 8 · 2022: 5 · 2021: 12 · 2020: 11 · 2019: 7 · 2018: 4 · 2017: 10 · 2016: 12 · 2015: 11 · 2014: 4 · 2013: 7 · 2012: 11
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- GlaxoSmithKline
- Monash University
- Medical Research Council
- National Health and Medical Research Council (299810, 436781)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- receptor activity-modifying proteins, RAMP1, RAMP3, RAMP2, amylin receptor, calcitonin receptor, cAMP signaling, calcium mobilization, ERK1/2 activation, Gαq
- MeSH terms
- Cyclic AMP, Amyloid, Animals, Chlorocebus aethiops, Humans, Membrane Proteins, Protein Binding, Signal Transduction, Receptors, Peptide, Receptors, Calcitonin, GTP-Binding Proteins, COS Cells, Receptors, G-Protein-Coupled, Intracellular Signaling Peptides and Proteins, Rats, Islet Amyloid Polypeptide, Receptor Activity-Modifying Proteins, Receptor Activity-Modifying Protein 1, Receptor Activity-Modifying Protein 3, Receptors, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
